Downloads

LIDE has one of the largest biobanks in the world due to the fresh patient samples collected daily from our hospital network. We have almost 1800 PDX models and 100 human cancer cell lines, both of which contain rare mutations and drug resistance.

MiniPDX® is an in-vivo version of a 3D organoid, and a faster alternative to PDX, without a lost in predictive power for drug response.

LIDE provides a one-stop solution with various immune-oncology platforms to support an all-around biologics R&D in immunotherapy.  We have also developed a unique human PBMC/cancer cell co-transfer model which can generate three-dimensional huPBMC-infiltrated tumor tissue for immunotherapy. 

Using fresh patient samples received daily from our hospital network, LIDE has established 1900+ high quality PDX models in more than 40 cancer types, many with rare mutations or drug resistance.

Imaging Mass Cytometry (IMC) is a relatively new technology and is an evolution of flow cytometry. IT uses metal-tagged antibodies (instead of fluorescence labeling) to enable high-throughput analysis and characterization of the tissue microenvironment, empowering researchers to investigate up to 35 markers simultaneously on a single section of tissue and up to 100 parameters in a single molecule (vs. about 18 max in traditional flow cytometry).

LIDE has established brain metastatic patient-derived orthotropic xenografts (PDOXs) models, including metastasis from breast and gastric cancers.

Our novel PDOX procedure converts hematological malignancies into an orthotopic model for robust efficacy studies. LIDE has established over 20 hematological malignancy patient-derived orthotropic xenografts (PDOXs) including AML, ALL, multiple myeloma, and different kinds of lymphoma.

CR cells allow for rapid and efficient expansion of cell cultures from patient tissue samples while maintaining the heterogeneity of the original cancer. LIDE has developed over 100 CR cells in which some of PDX matching CRCs exert special drug resistance/genetic alteration.